Servier completes the acquisition of Day One Biopharmaceuticals

CAR-T Digest - August 2020

23 April 2026: Servier completes the acquisition of Day One Biopharmaceuticals

Servier has completed the acquisition of Day One Biopharmaceuticals in a deal valued at approximately $2.5 billion, strengthening its strategic focus in oncology, particularly in rare cancers
The acquisition brings in Ojemda, an FDA-approved therapy for pediatric low-grade glioma, adding an already marketed product to Servier’s portfolio and reinforcing its leadership in this disease area
Beyond the commercial asset, the deal also expands Servier’s clinical-stage oncology pipeline, including programs such as emiltatug ledadotin (Emi-Le), an ADC, and DAY301, both targeting rare cancers with high unmet need
Strategically, the transaction enhances Servier’s presence in the U.S. oncology market while integrating Day One’s scientific and clinical capabilities to accelerate innovation in targeted therapies
Overall, this acquisition marks a significant step in Servier’s long-term oncology expansion strategy, combining a marketed therapy with a growing pipeline to advance treatments for patients with rare and difficult-to-treat cancers